Sunitinib

🧮 Dose calculator

Renal cell carcinoma · Regimen source: FDA Sutent · 2.1

• • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Sutent · 2.1
• • Adjuvant RCC: same schedule for up to 9 cycles. pNET: 37.5 mg continuously. FDA Sutent · 2.2FDA Sutent · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Sutent · 8.1

  “Risk Summary Based on animal reproduction studies and its mechanism of action, SUTENT can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] .”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Sutent · 8.2

  “Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with SUTENT and for at least 4 weeks after the last dose.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Sutent · 8.4

  “The safety and effectiveness of SUTENT in pediatric patients have not been established.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Sutent · 8.5

  “No overall differences in safety or effectiveness were observed between these patients and younger patients.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Sutent · 8.3

  “Contraception Females Advise females of reproductive potential to use effective contraception during treatment with SUTENT and for at least 4 weeks after the last dose.”